Phenotypic screening approaches for Chagas disease drug discovery

Chagas disease

(2018) José A Pérez-Molina et al.   LANCET

Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic  T. Cruzi Carriers

(2017) Carlos A. Morillo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial

(2017) Anis Rassi Jr et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Sexual transmission of American trypanosomiasis in humans: a new potential pandemic route for Chagas parasites

(2017) Perla F Araujo et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Opportunities and challenges in phenotypic drug discovery: an industry perspective

(2017) John G. Moffat et al.   NATURE REVIEWS DRUG DISCOVERY

Biological factors that impinge on Chagas disease drug development

(2017) AMANDA F. FRANCISCO et al.   PARASITOLOGY

Continual renewal and replication of persistentLeishmania majorparasites in concomitantly immune hosts

(2017) Michael A. Mandell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Community-Based Screening Program for Chagas Disease in the USA

(2017) Sheba K. Meymandi et al.   TRENDS IN PARASITOLOGY

Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participation

(2017) Paula Sartor et al.   PLoS Neglected Tropical Diseases

A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: The Bolivian Chagas Platform

(2017) Maria-Jesus Pinazo et al.   PLoS Neglected Tropical Diseases

Chagas disease research and development: Is there light at the end of the tunnel?

(2017) Eric Chatelain   Computational and Structural Biotechnology Journal

Drug target identification in protozoan parasites

(2016) Joachim Müller et al.   Expert Opinion on Drug Discovery

Genome Editing by CRISPR/Cas9: A Game Change in the Genetic Manipulation of Protists

(2016) Noelia Lander et al.   JOURNAL OF EUKARYOTIC MICROBIOLOGY

Natural Products as Sources of New Drugs from 1981 to 2014

(2016) David J. Newman et al.   JOURNAL OF NATURAL PRODUCTS

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

(2016) Shilpi Khare et al.   NATURE

Increased mortality attributed to Chagas disease: a systematic review and meta-analysis

(2016) Zulma M. Cucunubá et al.   Parasites & Vectors

Application of the CRISPR/Cas9 gene editing technique to research on functional genomes of parasites

(2016) Yubao Cui et al.   PARASITOLOGY INTERNATIONAL

High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala

(2016) Lucia Brum-Soares et al.   Revista da Sociedade Brasileira de Medicina Tropical

Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade

(2016) Manu De Rycker et al.   PLoS Neglected Tropical Diseases

Assessing anti- T. cruzi candidates in vitro for sterile cidality

(2016) Monica Cal et al.   International Journal for Parasitology-Drugs and Drug Resistance

Evaluation of Parameters Impacting Drug Susceptibility in Intracellular Trypanosoma cruzi Assay Protocols

(2016) Gyongseon Yang et al.   SLAS Discovery

Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults

(2015) Mario Javier Olivera et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease

(2015) Shilpi Khare et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers

(2015) I. Molina et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Between a bug and a hard place:Trypanosoma cruzigenetic diversity and the clinical outcomes of Chagas disease

(2015) Louisa A Messenger et al.   Expert Review of Anti-Infective Therapy

Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy

(2015) Carlos A. Morillo et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource

(2015) Imanol Peña et al.   Scientific Reports

Transcriptional and phenotypical heterogeneity ofTrypanosoma cruzicell populations

(2015) Víctor Seco-Hidalgo et al.   Open Biology

Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease

(2015) Jennifer Riley et al.   PLoS Neglected Tropical Diseases

Automated High-Content Assay for Compounds Selectively Toxic to Trypanosoma cruzi in a Myoblastic Cell Line

(2015) Julio Alonso-Padilla et al.   PLoS Neglected Tropical Diseases

Prevalence of Chagas Disease in Latin-American Migrants Living in Europe: A Systematic Review and Meta-analysis

(2015) Ana Requena-Méndez et al.   PLoS Neglected Tropical Diseases

Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease

(2015) Shilpi Khare et al.   PLoS Pathogens

Revisiting the Posttherapeutic Cure Criterion in Chagas Disease: Time for New Methods, More Questions, Doubts, and Polemics or Time to Change Old Concepts?

(2015) Marta de Lana et al.   Biomed Research International

Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes

(2015) Melissa L. Sykes et al.   International Journal for Parasitology-Drugs and Drug Resistance

Drug Strategies Targeting CYP51 in Neglected Tropical Diseases

(2014) Jun Yong Choi et al.   CHEMICAL REVIEWS

The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions - A comprehensive review

(2014) José Rodrigues Coura   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity

(2014) Bianca Zingales et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease

(2014) Israel Molina et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Image-Based Algorithm for Precise and Accurate High Throughput Assessment of Drug Activity against the Human Parasite Trypanosoma cruzi

(2014) Seunghyun Moon et al.   PLoS One

High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery

(2014) Julio Alonso-Padilla et al.   PLoS Neglected Tropical Diseases

Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines

(2013) D C Swinney   CLINICAL PHARMACOLOGY & THERAPEUTICS

Approaches to Protozoan Drug Discovery: Phenotypic Screening

(2013) Melissa L. Sykes et al.   JOURNAL OF MEDICINAL CHEMISTRY

Chagas disease in Australia and New Zealand: risks and needs for public health interventions

(2013) Yves Jackson et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Mode of Death on Chagas Heart Disease: Comparison with Other Etiologies. A Subanalysis of the REMADHE Prospective Trial

(2013) Silvia M. Ayub-Ferreira et al.   PLoS Neglected Tropical Diseases

Mortality due to Chagas disease in Brazil from 1979 to 2009: trends and regional differences

(2012) Francisco Rogerlândio Martins-Melo et al.   Journal of Infection in Developing Countries

Neglected Tropical Diseases as Hidden Causes of Cardiovascular Disease

(2012) Yasmin Moolani et al.   PLoS Neglected Tropical Diseases

Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51

(2012) Shamila S. Gunatilleke et al.   PLoS Neglected Tropical Diseases

Trypanosoma cruzi I diversity: Towards the need of genetic subdivision?

(2011) Felipe Guhl et al.   ACTA TROPICA

Finding New Hits in Neglected Disease Projects: Target or Phenotypic Based Screening?

(2011) Ian H. Gilbert et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Target Validation: Linking Target and Chemical Properties to Desired Product Profile

(2011) Paul G. Wyatt et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Methodological advances in drug discovery for Chagas disease

(2011) Juan M Bustamante et al.   Expert Opinion on Drug Discovery

Current status of Chagas disease chemotherapy

(2011) Paulo MM Guedes et al.   Expert Review of Anti-Infective Therapy

The revised Trypanosoma cruzi subspecific nomenclature: Rationale, epidemiological relevance and research applications

(2011) Bianca Zingales et al.   INFECTION GENETICS AND EVOLUTION

Visual Genome-Wide RNAi Screening to Identify Human Host Factors Required for Trypanosoma cruzi Infection

(2011) Auguste Genovesio et al.   PLoS One

Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease

(2010) J. C. Engel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identification and Optimization of Inhibitors of Trypanosomal Cysteine Proteases: Cruzain, Rhodesain, and TbCatB

(2010) Bryan T. Mott et al.   JOURNAL OF MEDICINAL CHEMISTRY

High-content imaging for automated determination of host-cell infection rate by the intracellular parasite Trypanosoma cruzi

(2010) L.L. Nohara et al.   PARASITOLOGY INTERNATIONAL

In Vitro and In Vivo High-Throughput Assays for the Testing of Anti-Trypanosoma cruzi Compounds

(2010) Adriana M. C. Canavaci et al.   PLoS Neglected Tropical Diseases

A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI

(2009) B Zingales et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

The role of parasite persistence in pathogenesis of Chagas heart disease

(2009) F. R. S. GUTIERREZ et al.   PARASITE IMMUNOLOGY

Identification of Three Classes of Heteroaromatic Compounds with Activity against Intracellular Trypanosoma cruzi by Chemical Library Screening

(2009) Esther Bettiol et al.   PLoS Neglected Tropical Diseases